PP01.01: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Latin America

PP01.03: Intrapulmonary Lymph Node Dissection for Early Lung Cancer in Latin America, Results from a Survey

PP01.04: Analysis of the Lipi Score as a Prognostic Factor in Advanced Non-Small Cell Lung Cancer

PP01.05: Comparison of Progression-Free Survival (PFS) in Patients With Non-Small Cell Lung Cancer (NSCLC) According to Their Actionable Mutations

PP01.07: Challenges in Molecular Testing in Non-Small Cell Lung Cancer (NSCLC) in Argentina. General Pathologist Real World Perspective

PP01.10: Effects of Respiratory Physiotherapy in Hospitalized Oncological Patients with Pleural Effusion

PP01.11: Clinical Outcomes of Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: Experience from an Oncology Center in Bogotá, Colombia

PP01.12: Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

PP01.13: Lung Resections for Non-Small Cell Lung Cancer in ‘Young Adults’: Excellent Prognosis and Other Clinicopathologic Features of 43 Cases

PP01.14: Thoracic Surgery Outcomes in Non-Small Cell Lung Cancer: Insights from a Colombian Thoracic Surgery Database

PP01.15: Machine Learning Models to Predict Operative Mortality in Thoracic Oncology Surgery for Non-Small Cell Lung Cancer

PP01.16: Primary and Metastatic Lung and Pleural Neoplasms Diagnosed at the Pathology Department of the National Cancer Institute of Colombia From 2020 to 2024

PP01.17: Health Systems Changes for Tobacco and Nicotine Dependence Treatment in Cancer Care and Other Clinical Settings

PP01.19: Surgery Improves the Survival of Thymic Epithelial Tumors (TETs) Patients Independently of Stage and Histological Subtype: Real-World Characteristics and Outcomes of a Brazilian Retrospective Cohort

PP01.21: Evaluating the Accuracy & Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries

PP01.22: Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center

PP01.24: Analysis of Survival and Factors Associated with Clinical Benefit and Death in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR gene mutations, experience at an institution

PP01.25: Exploring A>I(G) RNA Editing Patterns Linked to Cisplatin Sensitivity in LUAD Patients with Non-Actionable Mutations: Potential Biomarkers for Precision Oncology

PP01.26: Five Years (5y) Overall Survival (OS) With Targeted Therapy (TT) in Patients (pts) With Non-Small Cell Lung Cancer (aNSCLC) at a Comprehensive Cancer Center (CCC) in Colombia

PP01.28: Experiences of Informal Caregivers of Adult Patients with Lung Cancer in Chile: A Qualitative Study

PP01.29: Clinical and Economic Impact of the Availability of Innovative Therapies for Advanced Lung Cancer in Latin America

PP01.33: Amivantamab plus Chemotherapy as First-line Treatment Among Hispanic/Latinos harboring EGFR Exon 20 Insertions Mutated NSCLC: PAPILLON Subgroup Analysis

PP01.36: Metronomic Oral Cyclophosphamide (MOC) in Patients With Heavily Pretreated Metastatic Thymic Carcinoma: a Case Series

PP01.37: Early Experience With the FLAURA2 Regimen in Patients With NSCLC and EGFR Mutations in Latin America

PP01.41: Clinical Characteristics and Bronchoscopic Management of Patients with Malignant Central Airway Obstruction From 2017 to 2022 in Bogotá, Colombia

PP01.42: Analysis of EGFR, ALK, ROS1, and PDL1 Biomarkers in Advanced Non-Small Cell Lung Cancer in Argentina

PP01.44: Budget Impact Analysis for the Colombian Healthcare System of Participating in Sponsored Clinical Trials in Cancer: a Real-World Evidence Approach

PP01.49: FTIR Profiling of Serum Samples and its Association With Global DNA Methylation Percentage in Lung Cancer Patients

PP01.51: Osimertinib Plus Chemotherapy : Cardiac Toxicity - Stop or Continue. Case Report and Review of Literature

PP01.53: Construction and Validation of a Scale of Therapeutic Adherence to PulmonaryRehabilitation for mexican patients with Non Small Cells Lung Cancer (STA-PR-NSCLC):Preliminary Results

PP01.54: Experience of Pulmonary Rehabilitation in Patients With Oncological Diagnosis and Post-COVID Sequels

PP01.55: Innovations in Lipid-Based Nanocomposites for Theranostic Lung Cancer Therapy

PP01.57: Survival of Metastatic Lung Adenocarcinoma Among Women in a Single Colombian Cancer Center

PP01.58: Impact of Molecular Profiling on Clinical Management of LATAM Cancer Patients: Insights From a Next Generation Sequencing and Immunohistochemistry Panel

PP01.67: Solitary Pulmonary Nodule in Patients With Known Primary Cancer Site

PP01.72: Real-World Outcomes of First-Generation EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer in Uruguay.

PP01.73: Treatment Disparities in Advanced Non-Small Cell Lung Cancer in Uruguay

PP01.74: Real-World Data on Non-Small Cell Lung Cancer Treated With First-Line Checkpoint Inhibitors in a Latin American Institution

PP01.78: Fe3O4 Nanoparticles Coated With PEI Conjugated With Aptamers: Used as a new Diagnostic Tool for Lung Cancer

PP01.80: A World Map of Air Pollution and EGFR Prevalence

PP01.82: Mutational Profiling of Lung Cancer Using Next Generation Sequencing (NGS): A Real-World Clinical Diagnostic Experience among Hispanics

PP01.93: Relation Between Inflammation and Depression in Epidermal Growth Factor Receptor (EGFR) Positivefrfr Non-Small Cell Lung Cancer Patients

PP01.94: Characteristics and Outcomes of Hispanic Patients With RET-Rearrangement Non-Small Lung Cancer (NSCLC) Treated in Real-World Practice